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Christoph Bucher,1 Jo¨rg Halter,1 Dominik Heim,1 Andre Tichelli,1
Alois Gratwohl,1 Martin Stern1Cytomegalovirus (CMV) infection and graft-versus-host disease (GVHD) are important complications after
allogeneic hematopoietic stem cell transplantation (HSCT) with a clear link. Multiple studies show that
GVHD and its treatment put patients at risk for CMV replication. Data on CMV replication as a cause of
GVHD, in contrast, are controversial. We analyzed the reciprocal association of CMV replication with
acute GVHD (aGVHD) in 515 patients treated with allogeneic HSCT between 1993 and 2008.
Cumulative incidences at day 100 were 17% for CMV replication, 68% for aGVHD grade I-IV, and 48% for
GVHD grade II-IV. Multivariate time-dependent analyses revealed that the presence of GVHD increased
the risk of CMV replication in a dose-dependent manner: hazard ratio (HR) for CMV replication for patients
with aGVHD grade I was 1.35 (95% confidence interval [CI] 0.82-2.21); HR for patients with aGVHD grade II-
IV was 1.61 (95% CI 1.11-2.36, P-value for trend5 .01). During phases of CMV replication, patients were at
increased risk of developing aGVHD (HR 2.18, 95% CI 1.30-3.65, P\.01). These data confirm that GVHD
and its therapy can induce CMV replication. They further demonstrate the reciprocal novel finding that pa-
tients are at significantly increased risk of developing aGVHD during CMV replication.
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During the past 50 years hematopoietic stem cell
transplantation (HSCT) has evolved from experimen-
tal therapy to standard of care for many severe congen-
ital or acquired diseases of the bone marrow [1].
Despite progress in immunosuppressive and antiviral
therapy, acute graft-versus-host disease (aGVHD)
and cytomegalovirus (CMV) infection remain impor-
tant complications after allogeneic HSCT [2].
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[3-5]. In contrast, the role of CMV replication as
a cause of GVHD is controversial. Review articles on
the topic frequently suggest that CMV replication
might induce GVHD [6]; however, data that directly
link CMV replication and GVHD development are
lacking. One recent small study found no effect of
CMV replication on subsequent development of
aGVHD [7].
We were therefore interested to examine in a sin-
gle-center study the bidirectional association of
CMV replication and aGVHD in 515 patients treated
with T cell-replete allogeneic HSCT between 1993
and 2008.PATIENTS AND METHODS
Data Collection
This retrospective cohort study is based on stan-
dardized, prospectively collected clinical data from
the database of theDivision ofHematology at theUni-
versity Hospital of Basel, Switzerland, supplemented
by chart review of clinical records. Data on CMV as-
says were collected from the database of the Institute1309
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patients gave written informed consent to their treat-
ment and to analysis of transplant outcome data.
Patient Population
Between January 1st 1993 and December 31st
2008, 530 patients received 619 allogeneic HSCT.
For reasons of cohort homogeneity, 10 cord blood
transplants were excluded from the study, as were 73
T cell-depleted grafts, and 21 transplant procedures
with incomplete data on CMV replication. Data are
presented on the remaining 515 transplants performed
in 479 patients.
Median age at transplant was 42 years (range: 16-
70 years). Treatment indications were predominantly
hematologic malignancies (acute myeloid leukemia
(AML) 31%, acute lymphoblastic leukemia (ALL)
15%, chronic myelogenous leukemia (CML) 15%,
myelodysplastic syndrome (MDS) andmyeloprolifera-
tive neoplasia (MPN) 13%, and lymphoma 21%). Do-
nors were HLA-identical sibling (68%), other family
members (1%), or volunteer unrelated donors (28%
HLA-matched and 3% HLA-mismatched). The con-
ditioning regimen was primarily cyclophosphamide/
total-body irradiation (TBI) 6 etoposide (49%), cy-
clophosphamide/busulfan (17%), or fludarabine/TBI
(17%). GVHD prophylaxis consisted of cyclosporine
A (CSA) and methotrexate (71%) or CSA and myco-
phenolate mofetil (MMF) (21%) in the majority of
cases. Antithymocyte globulin (ATG) was adminis-
tered in 7% of transplants. The serologic CMV risk
constellation was donor negative/recipient negative
(D2/R2) in 33% of the patients, D1/R2 in 12%,
D1/R1 in 25%, D2/R1 in 19%, and missing in
11% of transplants. Further patient and transplant
characteristics are summarized in the Table 1.
CMV and GVHD Diagnosis and Treatment
We applied a standardized CMV surveillance pol-
icy over almost 2 decades. CMV replication was tested
weekly using pp65 antigenemia assay or real-time
polymerase chain reaction (PCR). PCR was intro-
duced routinely in November 2003, and was thereafter
performed in parallel to the antigenemia assay. Pa-
tients with detectable CMV replication were moni-
tored twice weekly. CMV replication was defined as
$1 positive cell per 105 peripheral blood mononuclear
cells (PBMCs) detected by CMV pp65 antigenemia as-
say, or $1000 CMV copies/mL whole EDTA-blood
detected by real-time PCR. Cytomegalovirus replica-
tion was preemptively treated with (val-)gancyclovir
or foscarnet until PCR or antigenemia were negative
in 2 consecutive assays. Severity and organ involve-
ment of aGVHD was assessed daily according to
established criteria [8,9]. Whenever possible,
diagnosis of GVHD was confirmed by skin or gutbiopsy. Isolated grade I GVHD of the skin was
treated with topical steroids. Any GVHD of grade II
or more was treated with systemic corticosteroids
(methylprednisolone 2 mg/kg/day).Statistical Analysis
Cumulative incidences of CMV replication and of
aGVHD were calculated, treating death from any
cause as a competing outcome.
To analyze the complex relationship between
CMV replication and aGVHD, 4 states were defined:
‘‘No CMV replication, no GVHD,’’ ‘‘CMV replica-
tion,’’ ‘‘aGVHD,’’ and ‘‘Dead.’’ All patients entered
the analysis in the ‘‘No CMV replication, no
GVHD’’ state at day of transplant. Patients transi-
tioned to a state of CMV replication on the day
CMV replication was detected for the first time, and
left this state on the day of the first negative assay. Pa-
tients with established GVHD remained in this state
until the end of the analysis (unless they developed
CMV replication or died). Possible transitions be-
tween the states are summarized in Figure 1. Transi-
tion probabilities between the states were compared
by calculating hazard ratios (HR) using time-
dependent Cox models adjusted for covariates (patient
age, disease, disease stage, donor type, stem cell
source, conditioning regimen, degree of HLA match,
and type of pharmacologic GVHD prophylaxis). To
analyze the impact of GVHD on CMV replication
we compared transition probabilities (1) (CMV repli-
cation in patient without GVHD) and (2) (CMV rep-
lication in patient with GVHD). To analyze the
impact of CMV replication on the occurrence of
GVHD, we compared transition probabilities (3)
(GVHD occurring in patient without CMV replica-
tion) and (4) (GVHD occurring in patient with
CMV replication).
Patient and transplant characteristics were com-
pared using Pearson’s chi-square or Mann-Whitney
U-test, as appropriate. Two-sided P-values \ .05
were considered significant. The analysis was re-
stricted to the time from transplant until day 100.RESULTS
Incidence of CMV Replication and aGVHD
CMV replication was found in 86 of 515 trans-
plants giving rise to a cumulative incidence at day
100 of 17% (95% confidence interval [CI] 14%-
20%). Median interval from transplant to CMV repli-
cation was 33 days (range: 1-95), and median duration
of CMV replication was 8.5 days (range: 2-62). Nine-
teen patients (4%) showed multiple episodes of CMV
replication within the first 100 days posttransplant.
Donor (D) and recipient (R) serostatus significantly
Table 1. Transplant Characteristics
Total transplants, n (%) 515 (100) Donor, n (%)
Sex, n (%) Identical Sibling 351 (68.2)
Male/female 299/216 (58.1/41.9) Other family member 5 (1.0)
Patient age Volunteer unrelated donor, HLA-matched 142 (27.6%)
Median (range) 42.0 (16-70) Volunteer unrelated donor, HLA-mismatched 17 (3.2%)
Age distribution, n (%) Conditioning regimen
<20 years 28 (5.4) Cyclophosphamide + TBI ± Etoposide 251 (48.7)
20-40 years 204 (39.6) Cyclophosphamide + Busulfan 88 (17.1)
>40 years 283 (55.0) Fludarabin + TBI 85 (16.5)
Underlying disease, n (%) Other 91 (17.7)
Acute leukemia 239 (46.4) GVHD prophylaxis, n (%)
Chronic myelogenous leukemia 79 (15.3) Cyclosporine A ± Methotrexate 400 (77.7)
Lymphoproliferative disease 109 (21.2) Cyclosporine A + Mycophenolate Mofetil 110 (21.3)
MDS/MPN 68 (13.2) Other 5 (1.0)
Other 20 (3.9) CMV constellation
Disease stage, n (%) Donor2/Recipient2 172 (33.4)
Early/advanced disease 202/313 (39.2/60.8) Donor+/Recipient2 61 (11.8)
Stem cell source, n (%) Donor+/Recipient+ 128 (24.9)
Bone marrow 110 (21.4) Donor2/Recipient+ 99 (19.2)
Peripheral blood 405 (78.6) Unknown 55 (10.7)
MDS indicates myelodysplastic syndrome; MPN, myeloproliferative neoplasia; TBI, total-body irradiation; GVHD, graft-versus-host disease; CMV,
cytomegalovirus.
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replication: D2/R2 6%, D1/R2 10%, D1/R1
25%, and D2/R1 37% (P\ .01). The introduction
of PCR for the detection of CMV led to a nonsignifi-
cant increase in the detection of CMV replication
compared to patients monitored by antigenemia only
(cumulative incidence of CMV replication at day 100
of 14.7% for patients tested with antigenemia assay
only versus 19.8% for patients tested with antigenemia
and PCR assays, P 5 .13).
The cumulative incidence for aGVHD grade I-IV
was 68% (95% CI 64%-72%) with a median onset at
day 14 (range: days 5-94); grade II-IV aGVHD oc-
curred in 48% of transplants (95% CI 45%-53%).
Combining both endpoints, 149 patients (29%) ex-
perienced neither aGVHD nor CMV replication, 280
(54%) aGVHD only, 19 (4%) CMV replication only,
and 67 (13%) both CMV replication and aGVHD.
Of the 67 patients with both aGVHD and CMV rep-
lication, 46 (69%) developed aGVHD prior to CMV
replication, 17 (25%) developed aGVHD during
CMV replication, and 4 (6%) developed aGVHD after
resolution of CMV replication.Figure 1. Summary representation of transitions analyzed in time-
dependent Cox models. All patients start in the ‘‘No CMV/No
GVHD’’ state at day of transplant, and transition to another state on
the day they develop CMV replication, or GVHD, or die. Arrows indi-
cate possible transitions: (1) CMV replication in patient without
GVHD; (2) CMV replication in patient with GVHD; (3) GVHDoccurring
in patient without CMV replication; (4) GVHD occurring in patient with
CMV replication.Effect of aGVHD on CMV Replication
Among the 86 patients with CMV replication, cy-
tomegalovirus replication initiated after onset of
GVHD in 46 (53%). Cox modeling revealed that the
presence of aGVHD grade I-IV significantly increased
the risk of CMV replication (HR 1.55, 95% CI 1.07-
2.23, P5 .02). As GVHD itself and GVHD treatment
are both immunosuppressive and may therefore con-
tribute to the increased risk of CMV reactivation, we
aimed to separate the direct influence of GVHD
from that of GVHD treatment. Compared to patients
without GVHD, we found a hazard ratio of 1.35 (95%CI 0.82-2.21) for patients with GVHD grade I (ie,
GVHD that was not treated with systemic steroids).
In comparison, patients with more severe GVHD
(grade II-IV, treated with systemic steroids) were at
a more increased risk for CMV replication (HR 1.61,
95% CI 1.11-2.36, overall P for trend [no GVHD/
GVHD grade I/GVHD grade II-IV] 5 .01, Table 2).
Median duration of CMV replication was shortest
in patients without GVHD (7 days). In comparison,
clearance of CMV was delayed both in patients with
GVHD at start of CMV replication (9 days) and in
those developing GVHD during CMV replication
(10 days), an effect compatible with slower virus clear-
ance in patients immunosuppressed by GVHD and its
Figure 2. Impact of aGVHD on duration and severity of CMV reactivation. Duration of CMV reactivation (A), first antigenemia during CMV replication
episode (pp65-positive cells/500,000 cells, B), and maximal CMVantigenemia (pp65-positive cells/500,000 cells, C) in episodes of CMV replication during
which GVHD occurred (left bar), episodes of CMV replication that initiated during established GVHD (middle bar), and isolated episodes of CMVoc-
curring in patients without GVHD (right bar). Lines represent medians, boxes interquartile ranges, and whiskers represent ranges.
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tion between the 3 cohorts did not reach statistical sig-
nificance, however (P 5 .64, Figure 2A).
The severity of CMV replication during estab-
lished GVHD (median pp65 positive cells at CMV di-
agnosis5 2/500,000 cells, median peak antigenemia 3/
500,000 cells) was similar to that of isolated CMV rep-
lication in patients occurring without GVHD (2/
500,000 and 2/500,000 cells, respectively) (P 5 .85
and P 5 .68 respectively, Figure 2B and C). Interest-
ingly, CMV episodes during which GVHD initiated
were more severe in comparison to isolated CMV rep-
lication without GVHD (4/500,000 cells and 8.5/
500,000 cells, P 5 .08 and P 5 .03, respectively,
Figure 2B and C). A similar trend was also seen in
the analysis of patients presenting with CMV disease:
6 cases of CMV pneumonitis and 2 cases of CMV co-
litis occurred up to day 100; CMV replication initiatedFigure 3. Impact of CMV replication on aGVHD incidence. Forest
plots representing the impact of CMV replication on GVHD incidence.
Each row represents a separate Cox model. Boxes represent the hazard
ratios derived from the Cox model, whiskers the 95% confidence inter-
vals. Hazard ratios were adjusted for patient age, disease, disease stage,
donor type, stem cell source, conditioning regimen, degree of HLA
match, and type of pharmacological GVHD prophylaxis.during GVHD in 7 of these 8 cases (HR for patients
during GVHD 8.58, P 5 .06).Effect of CMV Replication on aGVHD
In multivariate analysis, patients were at increased
risk of developing aGVHD during episodes of CMV
replication (HR for development of any grade
aGVHD: 2.18, 95%CI 1.30-3.65, P\ .01). Hazard ra-
tios for the development of grade II-IV aGVHD and
for involvement of skin, gut, and liver were compara-
ble, and are shown with 95% confidence intervals in
Figure 3.
Severity of aGVHD grade was not significantly
influenced by concomitant CMV replication: Median
grade of aGVHD was II in patients developing
GVHD during CMV replication, as well as in patients
with GVHD occurring before or after CMV replica-
tion (P 5 .62, Figure 4). Distribution and grade of
organ aGVHD were equally not significantly influ-
enced by concomitant CMV replication (Figure 4).
Finally, we analyzed the relationship between
CMV pretransplant serology and CMV replication.
The relative risk for GVHD development remained
virtually unchanged if donor/recipient CMV serology
were included in the model in addition to CMV repli-
cation (HR for CMV replication: 2.16, 95% CI 1.28-
3.65, P\ .01). In contrast, CMV serologic constella-
tion was not a significant predictor of GVHD after
correction for individual CMV replication (HR versus
D2/R2 1.00: D1/R2 0.90 [0.62-1.28], D2/R1 0.94
[0.71-1.26], D1/R1 1.18 [0.87-1.59]). These data
suggest that CMV replication rather than CMV seros-
tatus is the true risk factor for GVHD development.DISCUSSION
This retrospective single-center study examines
and describes the complex relationship between
Figure 4. Severity and organ distribution of GVHD episodes occurring
during CMV replication (black bars) and in the absence of CMV replica-
tion (gray bars).
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allogeneic HSCT.
The role of aGVHD as a risk factor for CMV dis-
ease is well known. Miller et al. [3], in 1986, described
aGVHD as an important risk factor for CMV replica-
tion. These early data also suggested a direct immuno-
suppressive effect of aGVHD independent from thatTable 2. Multivariate Analysis for CMV Reactivation at Day
100
Hazard Ratio (95% CI) P-Value
Acute GVHD
No acute GVHD 1.00
Acute GVHD grade I 1.35 (0.82-2.21) .01*
Acute GVHD grad II-IV 1.61 (1.11-2.36)
Graft
Bone marrow 1.00
Peripheral stem cells 0.70 (0.49-1.00) .05
Conditioning
Cyclophosphamide + TBI ±
Etoposide
1.00
Cyclophosphamide + Busulfan 0.88 (0.56-1.41) .60
Fludarabin + TBI 0.30 (0.12-0.78) .01
Other 1.13 (0.61-2.10) .69
CMV indicates cytomegalovirus; GVHD, graft-versus-host disease; TBI,
total-body irradiation.
Cox model adjusted for acute GVHD, patient age, disease, disease stage,
donor type, stem cell source, conditioning regimen, degree of HLA
match, and type of pharmacological GVHD prophylaxis.
*P-value for trend.of GVHD treatment (ie, systemic steroids), which in-
creases the risk of CMV replication. Multiple other
studies have since confirmed that patients with
aGVHD are at an increased risk of CMV disease [4,5].
The data in our current cohort are in line with
these studies, and confirm the association between
aGVHD and CMV replication. For patients with
aGVHDgrade II-IV (treated with systemic corticoste-
roids), we found a risk increase of 61% compared to
patients without GVHD. In comparison, the risk in-
crease of 35% documented in patients with aGVHD
I (not treated with systemic steroids) accounted for
more than half of the effect seen in aGVHD grade
II-IV patients, indicating that the immunosuppressive
effect of GVHD itself is at least as important as that of
GVHD treatment in the pathogenesis of CMV repli-
cation.
On the other hand, CMV may also play a role in
the development of GVHD. The increased risk of
GVHD development in patients with CMV seroposi-
tivity pretransplant [10-18] and reduced rates of
chronic GVHD (cGVHD) after preemptive CMV
treatment [19] are both indicative of a pathogenetic as-
sociation between CMV replication and aGVHD.
CMV-infected endothelial cells have been shown to
produce inflammatory cytokines such as interleukin
6, which plays a crucial role in the initial phase of the
GVHD [20]. The inflammatory response in patients
after allogeneic HSCT with CMV replication could
thereby contribute to the initiation of aGVHD [10].
However, data that directly link CMV replication
with aGVHD development are so far lacking [21,22].
Our large study provides this missing link and
clearly demonstrates that patients with active CMV
replication are at increased risk of developing aGVHD
in the transplant setting reported, which contains ama-
jority of patients receiving peripheral blood grafts after
myeloablative conditioning and leads to a high inci-
dence of aGVHD with an early onset. Our analysis
sheds light on the complex and reciprocal relationship
between CMV replication and mortality after HSCT:
since the introduction of a preemptive treatment,
CMV disease has become rare, and CMV replication
is no longer a substantial direct cause of death in pa-
tients after HSCT [23]. However, CMV remains
a clear risk factor for treatment-related mortality after
allogeneic HSCT [24]. This is elegantly explained by
the excess of aGVHD associated with CMV replica-
tion demonstrated in this study.
Although some studies have shown positive results
[25-27], most centers do not use antiviral prophylaxis
to prevent CMV replication, because of hematologic
(ie gancyclovir) and renal (ie foscarnet) toxicity, and
because preemptive treatment has proven to be very
successful in preventing CMV disease. In view of the
results our study, which showed that patients with
CMV replication are at increased risk for aGVHD,
1314 Biol Blood Marrow Transplant 16:1309-1314, 2010N. Cantoni et al.and consequently also for transplant-related mortality,
and of the introduction of new drugs, such as mariba-
vir, this policy has to be discussed. Maribavir is a new
antiviral drug under investigation for prophylaxis for
CMV [28]. A randomized, placebo-controlled dose-
ranging phase 2 study has been published with prom-
ising results, showing lower risk of CMV replication
and limited toxicity (principally gastrointestinal side
effects) [29]. The use of CMV prophylaxis routinely
with new agents with lower toxicity, especially in pa-
tients at high risk of CMV replication, might reduce
the incidence of CMV replications, reducing so the
risk for aGVHD.
In conclusion, this study confirms aGVHD as
a risk factor for CMV replication, and documents
that patients with activeCMV replication have a signif-
icantly higher risk of developing aGVHD compared to
patients without CMV replication. The data suggest
that prospective studies of prophylactic CMV
treatment to reduce aGVHD incidence might be
warranted.ACKNOWLEDGMENTS
Financial disclosure: The authors have nothing to
disclose.REFERENCES
1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N
Engl J Med. 2007;357:1472-1475.
2. Boeckh M, Ljungman P. How we treat cytomegalovirus in he-
matopoietic cell transplant recipients. Blood. 2009;113:
5711-5719.
3. MillerW, Flynn P, McCullough J, et al. Cytomegalovirus infec-
tion after bone marrow transplantation: an association with
acute graft-v-host disease. Blood. 1986;67:1162-1167.
4. Martino R, Rovira M, Carreras E, et al. Severe infections after
allogeneic peripheral blood stem cell transplantation:
a matched-pair comparison of unmanipulated and CD341
cell-selected transplantation. Haematologica. 2001;86:
1075-1086.
5. Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for
the development of cytomegalovirus disease after allogeneic
stem cell transplantation. Haematologica. 2006;91:78-83.
6. Appleton AL, Sviland L. Pathogenesis of GVHD: role of herpes
viruses. Bone Marrow Transplant. 1993;11:349-355.
7. Wang LR, Dong LJ, Zhang MJ, Lu DP. Correlations of human
herpesvirus 6B and CMV infection with acute GVHD in recip-
ients of allogeneic haematopoietic stem cell transplantation.
Bone Marrow Transplant. 2008;42:673-677.
8. Thomas E, Storb R, Clift RA, et al. Bone-marrow transplanta-
tion (first of two parts). N Engl J Med. 1975;292:832-843.
9. Deeg HJ, Storb R. Graft-versus-host disease: pathophysiologi-
cal and clinical aspects. Annu Rev Med. 1984;35:11-24.
10. Broers AE, van Der Holt R, van Esser JW, et al. Increased
transplant-related morbidity and mortality in CMV-
seropositive patients despite highly effective prevention of
CMV disease after allogeneic T-cell-depleted stem cell trans-
plantation. Blood. 2000;95:2240-2245.
11. Bostrom L, Ringden O, Sundberg B, Linde A, Tollemar J,
Nilsson B. Pretransplant herpesvirus serology and acute graft-
versus-host disease. Transplantation. 1988;46:548-552.12. Bostrom L, Ringden O, Gratama JW, Jacobsen N, Zwaan F,
Nilsson B. The impact of pretransplant herpesvirus serology
on acute and chronic graft-versus-host disease. Leukaemia
Working Party of the EuropeanGroup for BoneMarrowTrans-
plantation. Transplant Proc. 1990;22:206-207.
13. Lonnqvist B, Ringden O, Wahren B, Gahrton G, Lundgren G.
Cytomegalovirus infection associated with and preceding
chronic graft-versus-host disease. Transplantation. 1984;38:
465-468.
14. JacobsenN, AndersenHK, Skinhoj P, et al. Correlation between
donor cytomegalovirus immunity and chronic graft-versus-host
disease after allogeneic bone marrow transplantation. Scand J
Haematol. 1986;36:499-506.
15. Gratama JW, Fibbe WE, Naipal AM, et al. Cytomegalovirus
immunity and T lymphocytes in bone marrow donors and acute
graft-versus-host disease. Bone Marrow Transplant. 1986;1:
141-146.
16. Gratama JW, Zwaan FE, Stijnen T, et al. Herpes-virus immu-
nity and acute graft-versus-host disease. Lancet. 1987;1:471-474.
17. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D,
Cordonnier C. Donor CMV serologic status and outcome of
CMV-seropositive recipients after unrelated donor stem cell
transplantation: an EBMT megafile analysis. Blood. 2003;102:
4255-4260.
18. Ringden O, Schaffer M, Le Blanc K, et al. Which donor should
be chosen for hematopoietic stem cell transplantation among
unrelated HLA-A, -B, and -DRB1 genomically identical volun-
teers? Biol Blood Marrow Transplant. 2004;10:128-134.
19. Larsson K, Aschan J, Remberger M, Ringden O, Winiarski J,
Ljungman P. Reduced risk for extensive chronic graft-versus-
host disease in patients receiving transplants with human leuko-
cyte antigen-identical sibling donors given polymerase chain
reaction-based preemptive therapy against cytomegalovirus.
Transplantation. 2004;77:526-531.
20. Grefte A, van der Giessen M, van SonW, The TH. Circulating
cytomegalovirus (CMV)-infected endothelial cells in patients
with an active CMV infection. J Infect Dis. 1993;167:270-277.
21. Ringden O, Pihlstedt P, Markling L, et al. Prevention of graft-
versus-host disease with T cell depletion or cyclosporin and
methotrexate. A randomized trial in adult leukemic marrow re-
cipients. Bone Marrow Transplant. 1991;7:221-226.
22. Carlens S, Ringden O, Remberger M, et al. Risk factors for
chronic graft-versus-host disease after bone marrow transplan-
tation: a retrospective single centre analysis. BoneMarrow Trans-
plant. 1998;22:755-761.
23. Boeckh M, Nichols WG. The impact of cytomegalovirus seros-
tatus of donor and recipient before hematopoietic stem cell
transplantation in the era of antiviral prophylaxis and preemp-
tive therapy. Blood. 2004;103:2003-2008.
24. Gratwohl A, Stern M, Brand R, et al. Risk score for outcome af-
ter allogeneic hematopoietic stem cell transplantation: a retro-
spective analysis. Cancer. 2009;115:4715-4726.
25. Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention
of cytomegalovirus infection and disease after allogeneicmarrow
transplantation. N Engl J Med. 1988;318:70-75.
26. Winston DJ, HoWG, Bartoni K, et al. Ganciclovir prophylaxis
of cytomegalovirus infection and disease in allogeneic bonemar-
row transplant recipients. Results of a placebo-controlled, dou-
ble-blind trial. Ann Intern Med. 1993;118:179-184.
27. Griffiths P,Whitley R, SnydmanDR, SinghN, BoeckhM.Con-
temporary management of cytomegalovirus infection in trans-
plant recipients: guidelines from an IHMF workshop, 2007.
Herpes. 2008;15:4-12.
28. Trofe J, Pote L, Wade E, Blumberg E, Bloom RD. Maribavir:
a novel antiviral agent with activity against cytomegalovirus.
Ann Pharmacother. 2008;42:1447-1457.
29. WinstonDJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis
for prevention of cytomegalovirus infection in allogeneic stem
cell transplant recipients: a multicenter, randomized, double-
blind, placebo-controlled, dose-ranging study. Blood. 2008;111:
5403-5410.
